甲胎蛋白家用检测试纸(爱福陪)在肝癌高危人群中的应用价值研究
Study on the Application Value of α-Fetoprotein Household Test Paper (Aifupei) in a High Risk Group of Liver Cancer
DOI: 10.12677/ACM.2023.131015, PDF,  被引量    国家科技经费支持
作者: 伍维康:甘肃中医药大学大学公共卫生学院,甘肃 兰州;空军军医大学军事预防医学系军队防疫与流行病学教研室,特殊作业环境危害评估与防治教育部重点实验室,陕西 西安;黄 鑫, 付 婷, 肖 香, 王煚楠, 闫永平, 吉兆华*, 邵中军*:空军军医大学军事预防医学系军队防疫与流行病学教研室,特殊作业环境危害评估与防治教育部重点实验室,陕西 西安;刘义文:武威市疾病预防控制中心,甘肃 武威
关键词: 甲胎蛋白筛检肝癌化学发光法Alpha-Fetoprotein Screening Liver Cancer Chemiluminescence
摘要: 目的:评价国家“十二五”重大科技转化产品甲胎蛋白家用检测试纸(爱福陪)在肝癌高危人群中的应用价值。方法:收集国家传染病重大专项甘肃省武威市乙肝防治示范区乙肝抗原表面阳性的血清标本,采用爱福陪和化学发光法分别检测血清标本的甲胎蛋白,进行对比分析。结果:本研究共收集血清标本4277例,其中有肝癌患者104例(肝癌组),肝硬化402例(肝硬化组),乙肝患者2437例(乙肝患者组),乙肝携带者1334例(携带者组)。以化学发光法为金标准分析得出爱福陪检测甲胎蛋白灵敏度为22.5% (95% CI: 0.18~0.27),特异度96.9% (95% CI: 0.96~0.97),阳性预测值36.2% (95% CI: 0.29~0.43),阴性预测值94.1% (95% CI: 0.93~0.94),ROC曲线下分析显示爱福陪检测甲胎蛋白的AUC为0.597 (95% CI: 0.56~0.63)。爱福陪在肝癌组和肝硬化组的甲胎蛋白检出阳性率大于乙肝患者组以及乙肝病毒携带者组,且差异有统计学意义(P < 0.05)。结论:研究表明,爱福陪应用于肝硬化肝炎等人群可能比应用于全部乙肝表面抗原阳性人群效果较好。与化学发光法相比,爱福陪的灵敏度较低,但是特异度较高,操作简单方便,适用于无专业甲胎蛋白检测仪器基础医疗机构以及家庭内部进行甲胎蛋白检测。
Abstract: Objective: To evaluate the application value of AFP household test paper in the high-risk group of liver cancer. Methods: To collect the serum samples of hepatitis B antigen surface positive in the hepatitis B prevention and treatment demonstration area of Wuwei City, Gansu Province. The AFP of serum samples was detected by the methods of Aifupei and chemiluminescence, and carry out comparative analysis. Results: A total of 4277 serum samples were collected, among them, 104 pa-tients with liver cancer (HCC group), 402 cases of cirrhosis (cirrhosis group), Hepatitis B patients 2437 (hepatitis B patients group), Hepatitis B carrier 1334 cases (carrier group). By using chemi-luminescence as the gold standard, the sensitivity of Aifupei was 22.5% (95% CI: 0.025~0.037), specificity 96.9% (95% CI: 0.72~0.82), a positive predictive value of 36.2% (95% CI: 0.56~0.70), a sexual predictive value of 94.1% (95% CI: 0.05~0.07). The analysis under ROC curve showed that the AUC of alpha AFP was 0.597 (95 CI: 0.56~0.63). The positive rate of AFP in the liver cancer group and liver cirrhosis group was higher than that in the hepatitis B group and hepatitis B virus carrier group, the difference was statistically significant (P < 0.05). Conclusion: Studies have shown that the application of Aifupei in cirrhotic hepatitis and other populations may be better than the applica-tion of hepatitis B surface antigen positive population. Compared with the chemiluminescence method, the sensitivity of Aifupei company is low, but the specificity is high, the operation is simple and convenient, and it is suitable for self-test of AFP in basic medical institutions and in non-professional people outside the hospital.
文章引用:伍维康, 黄鑫, 付婷, 肖香, 王煚楠, 刘义文, 闫永平, 吉兆华, 邵中军. 甲胎蛋白家用检测试纸(爱福陪)在肝癌高危人群中的应用价值研究[J]. 临床医学进展, 2023, 13(1): 94-100. https://doi.org/10.12677/ACM.2023.131015

参考文献

[1] Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet, 391, 1301-1314. [Google Scholar] [CrossRef
[2] Wang, F.S., Fan, J.G., Zhang, Z., et al. (2014) The Global Burden of Liver Disease: The Major Impact of China. Hepatology, 60, 2099-2108. [Google Scholar] [CrossRef] [PubMed]
[3] Fan, J.H., Wang, J.B., Jiang, Y., et al. (2013) Attributable Causes of Liver Cancer Mortality and Incidence in China. Asian Pacific Journal of Cancer Prevention, 14, 7251-7256. [Google Scholar] [CrossRef
[4] 陈建国, 陆建华, 朱源荣, 等. 乙型肝炎病毒感染与肝癌发生的31年随访研究[J]. 中华流行病学杂志, 2010, 31(7): 721-726.
[5] 黄述婧, 娄金丽. 肝癌诊断技术方法应用进展[J]. 标记免疫分析与临床, 2016, 23(4): 466-469.
[6] 周晓萍. 血清甲胎蛋白检测方法及临床应用研究进展[J]. 内科, 2015, 10(2): 264-266.
[7] 朱源荣. 现场血清甲种胎儿蛋白普查与肝癌的早期诊断[J]. 中华肿瘤杂志, 1981, 3(1): 35-38.
[8] 闫永平, 邵中军, 吉兆华, 等. 甘肃省武威市乙肝防治示范区建设成效和展望[J]. 中国热带医学, 2019, 19(7): 608-609, 614.
[9] 王廷材, 吉兆华, 张琪, 等. 甘肃省武威市2005-2010年乙型病毒性肝炎发病趋势分析[J]. 中华疾病控制杂志, 2013, 17(3): 268-270.
[10] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版) [J]. 中华消化外科杂志, 2020, 19(1): 1-20.
[11] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.
[12] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 中华肝脏病杂志, 2019, 27(12): 938-961.
[13] Amarapurkar, D., Han, K.H., Chan, H.L., et al. (2009) Application of Surveillance Programs for Hepatocellular Carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology, 24, 955-961. [Google Scholar] [CrossRef] [PubMed]
[14] 沈小雷, 王海捷, 施启生, 等. 乙型肝炎病毒感染与肝癌关系的26年前瞻性定群观察[J]. 江苏预防医学, 2015, 26(5): 11-13.
[15] 李保荣. 《癌症早诊早治项目技术方案》评介[J]. 中华肿瘤杂志, 2011, 33(12): 949-950.
[16] 陆伦根. 原发性肝癌的早期筛查及诊断[J]. 临床肝胆病杂志, 2017, 33(7): 1257-1261.
[17] Ji, M., Liu, Z., Chang, E.T., et al. (2018) Mass Screening for Liver Cancer: Results from a Demonstration Screening Project in Zhongshan City, China. Scientific Reports, 8, Article No. 12787. [Google Scholar] [CrossRef] [PubMed]
[18] 羊文芳, 郑文雯, 苏显都, 等. 肿瘤标记物在肝癌患者血清中的表达及其诊断价值[J]. 解放军医学院学报, 2016, 37(9): 976-979, 1000.
[19] Heimbach, J.K., Kulik, L.M., Finn, R.S., et al. (2018) AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67, 358-380. [Google Scholar] [CrossRef] [PubMed]
[20] 金建国. 酶联免疫法、免疫胶体金法和电化学发光免疫分析法对乙型肝炎血清标志物的检测结果分析[J]. 中国医药指南, 2019, 17(36): 75-76.
[21] Tsuchiya, N., Sawada, Y., Endo, I., et al. (2015) Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 10573-10583. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, X.P., Wang, K. and Cheng, S.Q. (2018) Surveillance for Early-Stage Hepatocellular Carcinoma by Ultrasound plus Alpha-Fetoprotein Measurement: More De-tails, More Significance. Gastroenterology, 155, 1274-1275. [Google Scholar] [CrossRef] [PubMed]
[23] 陈建国, 张永辉, 朱健, 等. 启东肝癌的早诊早治及筛查效果评价[J]. 中华肿瘤杂志, 2017, 39(12): 946-951.